Fragasso Financial Advisors Inc Acquires 66 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Fragasso Financial Advisors Inc grew its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 12.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 613 shares of the medical equipment provider’s stock after acquiring an additional 66 shares during the quarter. Fragasso Financial Advisors Inc’s holdings in Intuitive Surgical were worth $273,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Mather Group LLC. increased its holdings in shares of Intuitive Surgical by 49.7% during the 2nd quarter. Mather Group LLC. now owns 2,371 shares of the medical equipment provider’s stock worth $1,055,000 after purchasing an additional 787 shares during the period. Douglas Lane & Associates LLC grew its position in Intuitive Surgical by 3.6% during the second quarter. Douglas Lane & Associates LLC now owns 39,388 shares of the medical equipment provider’s stock worth $17,522,000 after buying an additional 1,359 shares in the last quarter. Quent Capital LLC increased its stake in Intuitive Surgical by 2.4% during the second quarter. Quent Capital LLC now owns 1,334 shares of the medical equipment provider’s stock valued at $593,000 after acquiring an additional 31 shares during the period. City State Bank raised its stake in shares of Intuitive Surgical by 15.2% in the second quarter. City State Bank now owns 228 shares of the medical equipment provider’s stock valued at $101,000 after purchasing an additional 30 shares in the last quarter. Finally, Versant Capital Management Inc raised its stake in shares of Intuitive Surgical by 28.3% in the second quarter. Versant Capital Management Inc now owns 403 shares of the medical equipment provider’s stock valued at $179,000 after purchasing an additional 89 shares in the last quarter. 83.64% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

ISRG has been the topic of several analyst reports. Piper Sandler boosted their price target on shares of Intuitive Surgical from $490.00 to $495.00 and gave the company an “overweight” rating in a report on Friday, July 19th. Morgan Stanley upped their target price on shares of Intuitive Surgical from $375.00 to $460.00 and gave the company an “equal weight” rating in a research note on Monday, July 15th. JPMorgan Chase & Co. raised their price target on shares of Intuitive Surgical from $475.00 to $495.00 and gave the stock an “overweight” rating in a research note on Friday, July 19th. Stifel Nicolaus lifted their price objective on Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a report on Friday, July 19th. Finally, Citigroup increased their target price on Intuitive Surgical from $462.00 to $512.00 and gave the stock a “buy” rating in a report on Wednesday, July 10th. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $442.30.

Insiders Place Their Bets

In other news, SVP Mark Brosius sold 175 shares of the firm’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $389.16, for a total value of $68,103.00. Following the transaction, the senior vice president now owns 883 shares of the company’s stock, valued at approximately $343,628.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Intuitive Surgical news, SVP Mark Brosius sold 175 shares of the company’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $389.16, for a total transaction of $68,103.00. Following the completion of the sale, the senior vice president now owns 883 shares in the company, valued at approximately $343,628.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Craig H. Barratt sold 2,496 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $402.89, for a total value of $1,005,613.44. The disclosure for this sale can be found here. In the last three months, insiders sold 16,005 shares of company stock valued at $6,894,422. 0.90% of the stock is currently owned by insiders.

Intuitive Surgical Trading Up 2.2 %

Shares of Intuitive Surgical stock traded up $9.66 during midday trading on Tuesday, reaching $447.66. The company had a trading volume of 1,662,729 shares, compared to its average volume of 1,573,488. The stock has a fifty day simple moving average of $432.79 and a 200 day simple moving average of $402.15. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $468.78. The company has a market capitalization of $158.79 billion, a price-to-earnings ratio of 80.81, a price-to-earnings-growth ratio of 4.97 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, beating the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The company had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. During the same period last year, the firm earned $1.18 EPS. The business’s revenue for the quarter was up 14.5% on a year-over-year basis. Sell-side analysts expect that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.